Novel monoclonal treatments in severe asthma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Informa Healthcare Country of Publication: England NLM ID: 8106454 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4303 (Electronic) Linking ISSN: 02770903 NLM ISO Abbreviation: J Asthma Subsets: MEDLINE
    • Publication Information:
      Publication: London : Informa Healthcare
      Original Publication: [Ossining, N.Y. : Asthma Publications Society, c1981-
    • Subject Terms:
      Antibodies, Monoclonal, Humanized/*pharmacology ; Antibodies, Monoclonal, Humanized/*therapeutic use ; Asthma/*drug therapy ; Cytokines/*antagonists & inhibitors; Antibodies, Anti-Idiotypic/therapeutic use ; Cytokines/immunology ; Humans ; Immunoglobulin E/drug effects ; Interleukin-13/antagonists & inhibitors ; Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors ; Interleukin-5/antagonists & inhibitors ; Omalizumab/pharmacology ; Omalizumab/therapeutic use ; Quality of Life ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    • Abstract:
      Aim: To provide a general overview of the current biological treatments and discuss their potential anti-asthmatic effects.
      Data Sources: We reviewed articles in PubMed found using the search words "Asthma/therapy AND antibodies, monoclonal/therapeutic use AND cytokines."
      Study Selections: Only articles published in English since 2000 were considered. The search identified 29 studies; 8 additional studies were found by hand search, generating 37 studies.
      Results: Of the 37 studies investigating biological treatments of asthma, 5 were on the effects of anti-IgE (omalizumab); 12 on anti-IL-5; 8 on anti-IL-13; 5 on anti-IL-4R-α; 3 on anti-IL-9; one on TNF-α; one on anti-IL-2R-α; one on TSLP (Thymic Stromal Lymphopoietin); and one on OX40L. Sample sizes ranged from 3 to 943 participants. Studies of therapies targeting IgE, IL-2, IL4R-α, IL-5, and IL-13 showed some efficacy, whereas those targeting TSLP, IL-9, and TNF-α lacked convincing effectiveness.
      Conclusion: Research on the biological treatment of asthma shows promising results. While anti-IgE (omalizumab) has been used in the treatment of asthma for some years, anti-IL-5 has recently been approved for use. The efficacy of results of other large studies with a longer duration is needed to draw a firm conclusion. Such studies should not only focus on clinical outcomes, but also consider asthma-related quality of life. Knowledge on the asthma phenotypes and identification of biomarkers associated with these will be useful for physicians considering the right treatment for the asthma patient.
    • Contributed Indexing:
      Keywords: Asthma; monoclonal; review; treatment
    • Accession Number:
      0 (Antibodies, Anti-Idiotypic)
      0 (Antibodies, Monoclonal, Humanized)
      0 (Cytokines)
      0 (IL4R protein, human)
      0 (Interleukin-13)
      0 (Interleukin-4 Receptor alpha Subunit)
      0 (Interleukin-5)
      0 (Tumor Necrosis Factor-alpha)
      2P471X1Z11 (Omalizumab)
      37341-29-0 (Immunoglobulin E)
    • Publication Date:
      Date Created: 20170314 Date Completed: 20180105 Latest Revision: 20180105
    • Publication Date:
      20221213
    • Accession Number:
      10.1080/02770903.2017.1296157
    • Accession Number:
      28287273